• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Comprehensive Facts And Figures for the Protein Therapeutics Market, Including Main Players and Regional Break-Downs Are Provided In the December 2006 Report 'Global Protein Therapeutics Market'

Posted on: Thursday, 21 December 2006, 12:12 CST

Research and Markets (http://www.researchandmarkets.com/reports/c47534) has announced the addition of The Global Protein Therapeutics Market to their offering.

The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms.

This report examines each of the protein therapeutics classes in turn, assessing the market potential, and encompassing main therapeutic areas to which they are applicable.

The following product classes are analyzed in this report:

erythropoietins (EPO)

interferons

interleukins

insulin

monoclonal antibodies

blood-clotting factors

colony-stimulating factors (CSFs)

growth hormones

plasminogen activators

reproductive hormones

therapeutic enzymes

The report assesses the overall protein therapeutics market, key classes, and the factors influencing their historical and future performance. The report provides an overview of key products in each category, comparing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category, by region and by leading players and their products. Moreover, the report examines the promise of new drugs in each class and research and development efforts aimed at improving their delivery.

Finally, the future performance of the protein therapeutics market as a whole is examined against the background of pricing, emerging generic competition and manufacturing issues, indicating the likely trends in the coming years, and identifying possible solutions for problematic issues.

Key Features of this report:

Overview of the protein therapeutics environment, including main therapeutic categories, drug delivery technologies and key players

In-depth analysis of different classes of protein therapeutics, including key drugs in major therapeutic areas, as well as their advantages and disadvantages

Comprehensive facts and figures for the protein therapeutics market, including main players and regional break-downs

Future trends in the protein therapeutics marketplace, shaped by medical and technological advances as well as demographic and epidemiological changes and industry needs

Outlook for the protein therapeutics market, including manufacturing considerations and research into new methods of protein delivery

Who should buy this report?

Companies with a need to understand the protein therapeutics market and its place in the modern

pharmaceutical industry

Companies interested in understanding the impact and implications of product placement, lifecycle

management and competition in the protein therapeutics marketplace

Companies interested in understanding future opportunities in the protein therapeutics sector provided by

a combination of factors, including changing demographics and financial issues

Pharma/biotech companies wishing to identify potential protein therapeutics areas for partnerships and

collaboration in order to examine a variety of profit maximization strategies

Content Outline:

1 Methodology, Executive Summary and Overview

2 Challenges and Issues Facing the Therapeutic Protein Market

3 Erythropoietins

4 Interferons

5 Insulins

6 Monoclonal Antibodies

7 Blood-Clotting Factors

8 Colony-Stimulating Factors

9 Human Growth Hormones

10 Interleukins

11 Plasminogen Activators

12 Reproductive Hormones

13 Enzyme Replacement

14 Company Profiles

Tables

Graphs

Figures

Companies Mentioned:

Abbott Laboratories

Amgen

Amylin Pharmaceuticals

Anika Therapeutics

ArmaGen Technologies

Biogen Idec

BioMarin Pharmaceutical

BioMimetic Therapeutics

Bolder BioTechnology

Boston Life Sciences

Cambrex

Cambridge Antibody Technology

Ceregene

Chiron Corporation

Chugai Pharmaceutical

Coley Pharmaceutical Group

CuraGen

Curis Inc

Dragon Pharmaceuticals

1Enobia

Enzon

Eyetech Pharmaceuticals

FibroGen

FzioMed

GeneMedix

Genentech

Genmab

GenSci Regeneration Sciences

Genvec

Genzyme

Human Genome Sciences

ImClone Systems

Insmed

Janssen-Ortho

Johnson & Johnson

Maxygen

Medarex

MedImmune

OSI Pharmaceuticals

PeproTech

PDL Biopharma

Protein Polymer Technology

Raven Biotechnologies

Regeneron Pharmaceuticals

Rentschler Biotechnologie

Roche

Sangamo Biosciences

Scil Proteins

Serono

Spectrum Pharmaceuticals

Seattle Genetics

Stryker Biotech

1Theratechnologies

Transition Therapeutics

Vernalis Pharmaceuticals

Wockhardt

Wyeth

Xoma

ZymoGenetics

For more information visit http://www.researchandmarkets.com/reports/c47534

Source: Business Wire

More News in this Category